Abiopharma

🔍 MESDAG WILLEM (Executive)

Company: DESTINATION XL GROUP, INC. (DXLG)

Report Date: 2026-05-04

Detailed Transactions and Holdings:

• Holds 0 shares of Common Stock, $0.01 par value (Direct)
  Date: 2026-05-04 | Code: H | shares_owned_after: 2,593,758.00 | Footnotes: F1
• Acquired 58,373 shares of Deferred Stock Units at $0.621 per share (Derivative)
  Date: 2026-05-04 | Code: A | equity_swap_involved: false | shares_owned_after: 700,804.00 | transaction_form_type: 4 | Footnotes: F2, F3, F4, F5, F5

Footnotes:

• F1: The Reporting Person's ownership includes (i) 420,286 shares held by the Mesdag Family Limited Partnership, (ii) 97,529 shares held by the Mesdag Family Foundation, (iii), 44,746 shares held by the 2012 Mesdag Trust, (iv) 1,763,373 shares held by Red Mountain Capital Partners LLC, and (v) 267,824 shares held by Red Mountain Capital Management, Inc. The Reporting Person is the president, sole executive officer, sole director and sole shareholder of Red Mountain Capital Management, Inc. The Reporting Person disclaims beneficial ownership of the reported securities, except to the extent of his pecuniary interest therein. The filing system would not permit the filer to report his ownership as indirect.
• F2: Deferred Stock Units (DSUs) issued pursuant to the Director's elected form of compensation for quarterly annual retainer and committee chairperson fee.
• F3: The per share value is determined by the closing price of the Company's common stock on May 1, 2026.
• F4: Each DSU is credited to the Reporting Person under the Company's Director Plan (the "Director Plan"). Each DSU represents ownership equivalent to one share of the Company's common stock.
• F5: The DSUs credited under the Director Plan are payable in the form elected or provided under the Director Plan on the earlier of (i) the Reporting Person's date of separation of service, or (ii) upon death, disability or change in control as defined in the Director Plan.